This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. CAR-T cells forge ahead, Novartis reorganizes. Nat Biotechnol 34, 1079–1081 (2016). https://doi.org/10.1038/nbt1116-1079
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1116-1079
This article is cited by
-
First approval in sight for Novartis' CAR-T therapy after panel vote
Nature Biotechnology (2017)
-
Epic $12 billion deal and FDA's approval raise CAR-T to new heights
Nature Biotechnology (2017)